In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization

Ann Intern Med. 2020 Nov 17;173(10):JC51. doi: 10.7326/ACPJ202011170-051.

Abstract

Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24. 32865377.

Publication types

  • Comment

MeSH terms

  • Benzhydryl Compounds
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucosides / adverse effects
  • Heart Failure* / drug therapy
  • Hospitalization
  • Humans

Substances

  • Benzhydryl Compounds
  • Glucosides
  • empagliflozin